StarTric is looking forward to the next presentation of TriClover at PCR London Valves 2026, at a time when tricuspid valve repair is gaining momentum. Our Clinical Advisor, Antonio Mangieri, will present “TriClover: The next generation of tricuspid Transcatheter Edge-to-Edge Repair (T-TEER) technology” on Monday 23 November at 8:30, in a session on novel devices for tricuspid treatment, in discussion with Nicolo Piazza and Paul Sorajja and moderated by Azeem Latib and Jose (Pepe) Calle Gordo.
The timing matters. Results from the landmark investigator-led TRIC-I-HF (Tricuspid Intervention in Heart Failure) clinical trial, presented at ESC Congress 2026 and published in the article “Tricuspid-Valve Repair in Heart Failure” in the New England Journal of Medicine, show that adding transcatheter tricuspid repair to medical therapy significantly reduces all-cause death and heart failure hospitalisation, compared with medical therapy alone.
As T-TEER demonstrates its impact, treating tricuspid regurgitation (TR) with T-TEER devices is proving to be a clinical necessity rather than an option.
This is what we are working on at StarTric: a next-generation T-TEER device designed to make transcatheter TR repair effective in a broader patient population, with different valve anatomy. TriClover is designed as a standardised, single-device procedure that adapts to different tricuspid valve morphology, rather than requiring the valve to suit the device.
As we complete preclinical work and prepare to move into the clinical phase, Antonio’s presentation is an important moment for us. We look forward to connecting with clinicians, investors and strategic partners across the structural heart community in London.
